title: Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis.
abstract: An objective approach for monitoring the treatment of acute pulmonary exacerbation in cystic fibrosis was evaluated. Eleven biochemical markers of inflammation (erythrocyte sedimentation rate, neutrophil count, C-reactive protein, alpha-1 antitrypsin, haptoglobin, ceruloplasmin, fibronectin, alpha-1 glycoprotein, alpha-2 macroglobulin, C3, granulocyte elastase and anti-Pseudomonas IgG) were measured in blood serum and plasma from 46 cystic fibrosis patients with chronic Pseudomonas aeruginosa colonization before and after treatment. The overall outcome in each patient was evaluated by means of a pondered sum of clinical, chest X-ray and lung function scores. Biochemical markers were related to the overall clinical improvement: haptoglobin, ceruloplasmin, fibronectin and alpha-1 glycoprotein showed a good sensitivity (64-70%), specificity (60-70%) and positive predictive value (86-89%). Granulocyte elastase showed a similar sensitivity (67%) and positive predictive value (85%) but a lower specificity (33%). The negative predictive value was generally poor (32-39%). Our data suggest that the combined measurement of some markers of inflammation and of conventional clinical parameters, may help in evaluating the efficacy of anti-infective treatment in cystic fibrosis.
authors.affiliation: Cystic Fibrosis Center, Verona, Italy.
authors.forename: E A
authors.initials: EA
authors.lastname: Valletta
authors.forename: A
authors.initials: A
authors.lastname: Rigo
authors.forename: L
authors.initials: L
authors.lastname: Bonazzi
authors.forename: L
authors.initials: L
authors.lastname: Zanolla
authors.forename: G
authors.initials: G
authors.lastname: Mastella
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D002570:Ceruloplasmin / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications*; D016903:Drug Monitoring; D005260:Female; D005353:Fibronectins / Q000097:blood; D006023:Glycoproteins; D006098:Granulocytes / Q000201:enzymology; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins; D008297:Male; D010196:Pancreatic Elastase / Q000097:blood; D011014:Pneumonia / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D011552:Pseudomonas Infections / Q000097:blood* / Q000188:drug therapy / Q000209:etiology
chemical_list: C048566:A1BG protein, human; D000890:Anti-Infective Agents; D015415:Biomarkers; D001798:Blood Proteins; D005353:Fibronectins; D006023:Glycoproteins; D006242:Haptoglobins; D007136:Immunoglobulins; D002570:Ceruloplasmin; D010196:Pancreatic Elastase